|
Ubiquitin, Ubiquitin-like Proteins, their Derivatives,
Proteasone and Complexes
 |
Ubiquitin & UBL Signaling
/ Enzo Life Sciences
Richiedi cartaceo / 40
pagine.
Scarica pdf (3,26 Mb)
Proteins & Derivatives
Activating Enzymes (E1s)
Conjugating Enzymes (E2s)
Ligases (E3s)
Deconjugating Enzymes (DCEs)
Target/Substrate Proteins Detection & Isolation Kits & Components
Proteasome & Related Complexes |
K63-Linkage-Specific Antibody
2
pagine.
Scarica pdf (1,14 Mb)
Recognises K63-LINKED POLYUBIQUITIN CHAINS, but not any other
isopeptide-linked polyubiquitin chain or monoubiquitin |
 |
 |
Ubiquitin and UBL
Chains
2
pagine.
Scarica pdf (0,8 Mb)
Substrates for deubiquitinylating enzyme assays and Polyubiquitin
Binding Studies |
PROTEASOME ELISA KIT
2 pagine
Scarica pdf (1 Mb)
Determination of proteasome levels in biological samples (cell lysates,
tissue extracts, plasma, serum)
Comparison of proteasome levels in plasma/serum samples associated
with a particular disease/illness with samples from healthy controls
Investigation of variation in proteasome levels in response to
inhibitors and activators |
 |
 |
UBIQAPTURE-Q KIT
2
pagine.
Scarica pdf (1 Mb)
An efficient tool for the isolation and enrichment
of ubiquitinylated proteins |
Ubiquitin-like proteins
Over recent years a number of proteins related to ubiquitin
have been identified. These ubiquitin-like proteins fall into two separate
classes, namely type I and type II. The type I proteins (UBLs) function as
modifiers in a manner analogous to that of ubiquitin and exist either in a free
form or attached covalently to other proteins by their C-termini. Type II
proteins bear domains that are related to ubiquitin but are otherwise unrelated
in sequence to each other (termed ubiquitin-domain proteins or UDPs). In
contrast to the ubiquitin-like modifiers the UDPs are not conjugated to other
proteins.
|
All currently known UBLs are
related in sequence to ubiquitin to a greater or lesser extent. Whilst
APG12, URM1 and FAT10 are expressed as mature proteins, all other UBLs
(including ubiquitin) are expressed as inactive precursors made
initially as fusions with C-terminal extensions. These tails, which
prevent conjugation, can be either single amino acids or polypeptides.
The precursors are processed endoproteolytically by specific proteases,
and the modifiers and their respective tails are released.
|
Type I (UBLs)
FAT10
Fub1
ISG15 (UCRP)
NEDD8
SUMO-1, 2, 3
UBL5
Urm1
Ubiquitin
Apg12
|
Type II (UDPs)HHR23A/B
Dsk2
Plic1/2
Bag1
Chap1/2
Parkin
Elongin B
Ubp6
Scythe
|
The conjugation pathways for the UBLs elucidated to date
closely resemble that for ubiquitin, although in some cases the E1 and E2
enzymes have yet to be identified.
FAT10
Encoded in the major histocompatibility complex class I locus and is
synergistically inducible with interferon-gamma and tumor necrosis factor
alpha1. FAT10 expression causes apoptosis and is inducible with tumour necrosis
factor alpha2 and it appears that FAT10 may modulate tumorigenesis through its
interaction with the MAD2 spindle-assembly checkpoint protein3. It has been
demonstrated that FAT10 and its conjugates are rapidly degraded by the
proteasome. Furthermore, a new interaction partner of FAT10, NEDD8 ultimate
buster-1L (NUB1L), may function as a linker that targets FAT10 for degradation
by the proteasome4.
1.Y.C. Liu et al. Proc. Natl. Acad. Sci. USA 1999 96 4313
2.S. Raasi et al. J. Biol. Chem. 2001 276 35334
3.C.G. Lee et al. Oncogene 2003 22 2592
4.M.S. Hipp et al. J. Biol. Chem. 2004 279 16503
Fub1
Belongs to the ubiquitin-like protein group that is capable of forming
conjugates to other proteins and shows amino acid sequence similarity to that of
ubiquitin1. Certain cloned cDNAs encode for a single ubiquitin-like (Fub1)
protein fused in frame to S30, a protein of the small ribosomal subunit.
Purified ubiquicidin indicates that it is identical to S30 produced by
post-translational processing of the fau protein2. Fub1 may act as a substitute
or inhibitor of ubiquitin, to which it is most closely related, or to the close
ubiquitin-like relatives UCRP, FAT10, and/or NEDD83.
1.L. Michiels et al. Oncogene 1993 8 2537
2.P.S. Hiemstra et al. Leukoc. Biol. 1999 66 423
3.T.G. Rossman et al. Oncogene 2003 22 1817
ISG15 (ISG15
UBE1L
- ISG15-activating enzyme)
Originally identified as an interferon stimulated gene (ISG) whose expression is
highly induced upon interferon treatment1. ISG15 contains two ubiquitin homology
domains in tandem and shows ~30% identity to ubiquitin. ISG15 is conserved in
dispersed regions and homology among the five identified mammalian proteins is
around 47%. It is synthesized as a 17 kDa precursor form and processed to 15 kDa
protein by a specific protease in order to expose di-glycine residues at the
carboxyl terminus, which is critical for subsequent conjugation to target
proteins2. The ability of ISG15 to be conjugated to the other cellular proteins
has been identified3. UBE1L (ISG15-activating enzyme) and UBP43 (deISGylating
enzyme), share a significant homology with counterparts of ubiquitin system4.
ISGylation may play important roles in viral or bacterial infection where
protein ISGylation is highly induced5.
1.P.J. Farrell et al. Nature 1979 279 523
2.E. Knight Jr. et al. J. Biol. Chem. 1988 263 4520
3.K.R. Loeb et al. J. Biol. Chem. 1992 267 7806
4.K. Kok et al. Proc. Natl. Acad. Sci. USA 1993 90 6071
5.C.E. Samuel Clin. Microbiol. 2001 14 778
NEDD8 (pro-NEDD8
Neddylation)
Shares ~60% identity with ubiquitin at the amino
acid level, that can be covalently conjugated (neddylation) to a limited number
of cellular proteins in a fashion similar to that of ubiquitin. The C-terminus
of pro-NEDD8 is processed to expose glycine76 in the mature form. This
processing is required for conjugation to target proteins via a range of
specific activating and conjugating enzymes1. Neddylation acts to regulate the
function of ubiquitin-protein ligases (E3s) and organisms with lesions in the
neddylation process exhibit severe growth defects2. Substrates for neddylation
include the von Hippel-Lindau (VHL) tumour suppressor gene3 and the tumour
suppressor and transcriptional regulator p534 amongst others.
1.L. Gong et al. J. Biol. Chem. 1999 274 12036
2.G. Perry et al. Cell Dev. Biol. 2004 15 221
3.N.H. Stickle et al. Mol. Cell Biol. 2004 24 3251
4.J.W. Harper Cell 2004 118 2
SUMO (SUMO
-
SUMO family
members)
SUMO is present in all eukaryotic kingdoms and is highly conserved from yeast to
humans1. Whereas invertebrates have only one SUMO gene, three members of the
SUMO family have een described in vertebrates. SUMO-1 and the close
homologuesSUMO-2 and SUMO-3, with some 50% homology between UMO-1 and SUMO-2/3.
A fourth SUMO (SUMO-4) has been reported2, however, there is debate over its
expression as a functional protein. The SUMO family members are expressed with
short C-terminal extensions (the pro-forms), which are processed to expose the
C-terminal glycine residue that is essential for conjugation to target proteins
(the mature forms). An increasing number of SUMO substrates are being described
including RanGAP1, SP100, PML and IκBα proteins3. Unlike ubiquitin, SUMO does
not appear to target proteins for degradation, but seems to be involved in the
modulation of protein-protein interactions. Although having only 18% amino acid
sequence identity with ubiquitin, the overall structure closely resembles that
of ubiquitin. Whereas the two C-terminal glycine residues required for
isopeptide bond formation are conserved between the two molecules, Lys48 found
in ubiquitin, and required to generate ubiquitin polymers, is substituted by
Gln69 in SUMO-1 thereby providing an explanation of why SUMO-1 has not been
observed to form polymers4. However, SUMO-2 and SUMO-3 sequences both contain
the consensus SUMO-modification site, as a consequence of which the
SUMO-activating and conjugating enzymes may catalyze the formation of polymeric
chains of SUMO-2 and SUMO-3 on protein substrates5.
1.S. Mller et al. Nat. Rev. Mol. Cell Biol. 2001 2 202
2.K. Bohren et al. J. Biol. Chem 2004 279 27233
3.C. Kretz-Remy and R.M. Tanguay Biochem. Cell Biol. 1999 77 299
4.P. Bayer et al. Nat. Rev. Mol. Cell Biol. 1998 10 275
5.M.H. Tathman et al. J. Biol. Chem. 2001 276 35368
UBL5
Initially identified in a screen for highly expressed genes in human iris1. The
gene encodes a protein of 73 amino acids with a molecular weight of 8.5 kDa.
Orthologs of UBL5 occur in every eukaryotic genome characterized to date, which
suggests an important function for UBL5. The amino acid sequence of UBL5 is
identical to that of Beacon2, a protein reported to be involved in feeding
behaviour and development of obesity and type 2 diabetes in the Israeli sand rat
Psammomys obeseus, and it may also interact with the cyclin-like kinase CLK42.
The yeast ortholog of UBL5, HUB1, has recently been demonstrated to be an
essential gene, whose loss results in cell cycle defects, inefficient pre-mRNA
splicing, and incorrect sub-cellular targeting3. Based on sequence homology and
structure prediction algorithms it has been demonstrated that the protein
structure of UBL5 is very similar to that of ubiquitin despite the low,
approximately 25%, residue similarity4.
1.J.S. Friedmann et al. Genomics 2001 71 252
2.G.R. Collier et al. Diabetes 2000 49 1766
3.C.R. Wilkinson et al. Curr. Biol. 2004 14 2283
4.T. McNally et al. Prot. Sci. 2003 12 1562
Urm1
Urm1 acts as a post-translational protein modifier in Saccharomyces cerevisiae1.
Simultaneous loss of Urm1p and Cla4p, a p21-activated kinase that functions in
budding, is lethal, suggesting a role for the urmylation pathway in budding
whilst additional results suggest an involvement in nutrient sensing2. The first
in vivo target for the urmylation pathway has been identified as the antioxidant
protein Ahp1p. It has been suggested that the conjugation of Urm1p to Ahp1p
could regulate the function of Ahp1p in antioxidant stress response in
Saccharomyces cerevisiae3.
1.K. Furukawa et al. J. Biol. Chem. 2000 275 7462
2.A.S. Goehring et al. Mol. Biol. Cell 2003 14 4329
3.A.S. Goehring et al. Eukaryot. Cell 2003 2 930
| | |